Completed PHASE4 INTERVENTIONAL NCT00142558

A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)

A Randomized, Double-Blind, Active-Comparator-Controlled 5-Day Trial of the Effect of Etoricoxib 120 mg Versus Indomethacin 150 mg in the Treatment of Acute Gout

Sponsor: Organon and Co

Conditions Acute Gout

Interventions Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days MK0663; etoricoxib / Duration of Treatment: 5 Days

Updated 9 times since 2017 Last updated: Aug 12, 2024 Started: Jan 1, 2005 Primary completion: May 1, 2005 Completion: May 1, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Acute Gout, this trial is completed. The trial is conducted by Organon and Co and has accumulated 9 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Mar 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Mar 2022 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
May 2017 — Jun 2018 [monthly]

Completed PHASE4
Feb 2017 — May 2017 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Organon and Co

Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.